ʻO Tadalafil 171596-29-5 e mālama i ka Erectile Dysfunction i nā kāne

Loaʻa iā Tadalafil (Tadalafil, Tadalafil) ka molecular formula o C22H19N3O4 a me ke kaumaha mole o 389.4. Ua hoʻohana nui ʻia i ka mālama ʻana i ka male erectile male mai 2003, me ka inoa kālepa Cialis (Cialis). I Iune 2009, ua ʻae ka FDA i ka tadalafil ma ʻAmelika Hui Pū ʻIa no ka mālama ʻana i nā maʻi me ka pulmonary arterial hypertension (PAH) ma lalo o ka inoa kālepa Adcirca. Ua hoʻokomo ʻia ʻo Tadalafil ma 2003 ma ke ʻano he lāʻau lapaʻau no ka mālama ʻana iā ED. Hoʻohana ia i ka hopena 30 mau minuke ma hope o ka hoʻoponopono ʻana, akā ʻo kona hopena maikaʻi loa ʻo 2h ma hope o ka hoʻomaka ʻana o ka hana, a hiki i ka hopena ke hoʻomau no 36h, a ʻaʻole pili ka hopena i ka meaʻai. ʻO ka nui o ka tadalafil he 10 a i ʻole 20 mg, ʻo ka mea i manaʻo ʻia he 10 mg, a ua hoʻoponopono ʻia ke ʻano e like me ka pane a ka mea maʻi a me nā hopena ʻino. Ua hōʻike ʻia nā haʻawina ma mua o ka mākeke ma hope o ka hoʻokele waha o 10 a i ʻole 20 mg o tadalafil no nā wiki he 12, ʻo 67% a me 81% ka uku kūpono. Ua hōʻike ʻia nā haʻawina he nui ʻoi aku ka maikaʻi o ka tadalafil i ka mālama ʻana iā ED.

Erectile Dysfunction: ʻO Tadalafil kahi koho phosphodiesterase type 5 (PDE5) e like me ka sildenafil, akā ʻokoʻa kona ʻano mai ka mea hope loa, a ʻaʻole e hoʻopilikia ka meaʻai momona i kona absorption. Ma lalo o ka hana o ka hoʻoulu ʻana i ka wahine, ka nitric oxide synthase (NOS) i loko o nā penile nerve endings a me nā cell endothelial vascular e hoʻopaʻa i ka synthesis o ka nitric oxide (NO) mai ka substrate L-arginine. NO ka ho'āla i ka guanylate cyclase, ka mea e hoʻohuli ai i ka guanosine triphosphate i ka cyclic guanosine monophosphate (cGMP), a laila e hoʻoulu ai i ka cyclic guanosine monophosphate-dependent protein kinase, ka hopena i ka emi ʻana o ka neʻe ʻana o ka calcium i loko o nā ʻiʻo ʻiʻo maʻemaʻe. Hoʻohaʻahaʻa ka Phosphodiesterase type 5 (PDE5) i ka cGMP i nā huahana hana ʻole, e hoʻolilo i ka penis i kahi kūlana nāwaliwali. Hoʻopiliʻo Tadalafil i ka hoʻohaʻahaʻaʻana o PDE5, e alakaʻi ana i ka hōʻiliʻili o cGMP, kahi e hoʻomaha ai i kaʻiʻo maʻemaʻe o ka corpus cavernosum, e alakaʻi ana i ka penile. No ka mea ʻaʻohe mea hāʻawi ʻo nitrates, ʻo ka hoʻohana pū ʻana me ka tadalafil e hoʻonui nui i ke kiʻekiʻe o cGMP a alakaʻi i ka hypotension koʻikoʻi. No laila, ua contraindicated ka hoʻohana pū ʻana o nā mea ʻelua i ka hana lapaʻau.

Hana ʻo Tadalafil ma ke kāohi ʻana i ka PDES. Hoʻohaʻahaʻa ʻia ka GMP, no laila hiki i ka hoʻohana ʻana me nā nitrates ke hoʻohaʻahaʻa loa i ke kahe koko a hoʻonui i ka pilikia o ka syncope. CY3PA4 inducers e hoemi i ka bioavailability o tadanafil, a me ka hui pu ana me rifampicin, cimetidine, erythromycin, clarithromycin, itracon, ketocon, a me HVI protease inhibitors hiki ke hoonui i ka Pono e hoʻololi i ke koko o ka lāʻau. I kēia manawa, ʻaʻohe hōʻike e pili ana nā ʻāpana pharmacokinetic o kēia huahana e ka meaʻai a me ka waiʻona.